Head and neck cancers (HNCs) account for approximately 10% of all cancers with about 90% of them being squamous cell carcinoma. Surgery represents the mainstay of treatment for small, well-localized, and low-grade salivary gland carcinomas. In a clinical trial of BNCT, it was especially effective for patients with recurrent salivary gland carcinomas; the 3-year overall survival rate was about 60% or more. A clinical trial using accelerators in Japan on 13 recurrent and locally advanced non-SCC patients showed an overall response rate of 69.2%; the disease control rate was 100%, with a 1-y/2-y overall survival rate of 100/100%, respectively.